{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:18:29Z","timestamp":1793121509442,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.breast.2026.104693","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T16:21:48Z","timestamp":1767457308000},"page":"104693","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Cost-effectiveness of inavolisib plus palbociclib-fulvestrant versus palbociclib plus fulvestrant as first-line treatment in HR+\/HER2-advanced breast cancer"],"prefix":"10.1016","volume":"85","author":[{"given":"Jiaming","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengxiong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2026.104693_bib1","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA: a cancer journal for clinicians"},{"key":"10.1016\/j.breast.2026.104693_bib2","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1097\/CM9.0000000000003442","article-title":"Comparative analysis of cancer statistics in China and the United States in 2024","volume":"137","author":"Wu","year":"2024","journal-title":"Chinese medical journal"},{"key":"10.1016\/j.breast.2026.104693_bib3","first-page":"477","article-title":"Breast cancer statistics 2024","volume":"74","author":"Giaquinto","year":"2024","journal-title":"CA: a cancer journal for clinicians"},{"key":"10.1016\/j.breast.2026.104693_bib4","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1056\/NEJMoa2501796","article-title":"Overall survival with inavolisib in PIK3CA-Mutated advanced breast cancer","volume":"393","author":"Jhaveri","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104693_bib5","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1080\/13696998.2024.2439228","article-title":"Real-world perioperative treatment patterns and economic burden of recurrence in early-stage HER2-negative breast cancer: a SEER-medicare study","volume":"28","author":"Earla","year":"2025","journal-title":"J Med Econ"},{"key":"10.1016\/j.breast.2026.104693_bib6","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1007\/s12325-024-02893-y","article-title":"Direct and indirect costs of breast cancer and associated implications: a systematic review","volume":"41","author":"Franklin","year":"2024","journal-title":"Adv Ther"},{"key":"10.1016\/j.breast.2026.104693_bib7","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/BF02967635","article-title":"Endocrine-resistant breast cancer: underlying mechanisms and strategies for overcoming resistance","volume":"10","author":"Kurebayashi","year":"2003","journal-title":"Breast cancer (Tokyo, Japan)"},{"key":"10.1016\/j.breast.2026.104693_bib8","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.annonc.2020.11.011","article-title":"Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1","volume":"32","author":"Andr\u00e9","year":"2021","journal-title":"Ann Oncol : official journal of the European Society for Medical Oncology"},{"key":"10.1016\/j.breast.2026.104693_bib9","doi-asserted-by":"crossref","first-page":"331","DOI":"10.6004\/jnccn.2024.0035","article-title":"Breast cancer, version 3.2024, NCCN Clinical practice Guidelines in oncology","volume":"22","author":"Gradishar","year":"2024","journal-title":"J Natl Compr Cancer Netw : J Natl Compr Cancer Netw"},{"key":"10.1016\/j.breast.2026.104693_bib10","article-title":"Lurbinectedin sensitizes PD-L1 blockade therapy by activating STING-IFN signaling in small-cell lung cancer","volume":"5","author":"Chakraborty","year":"2024","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.breast.2026.104693_bib11","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s40425-018-0440-9","article-title":"Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma","volume":"6","author":"Wu","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.breast.2026.104693_bib12","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104693_bib13","series-title":"China guidelines for pharmacoeconomic evaluations","first-page":"1","author":"Liu","year":"2020"},{"key":"10.1016\/j.breast.2026.104693_bib14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.breast.2026.104693_bib15","series-title":"ASP drug pricing files","year":"2025"},{"key":"10.1016\/j.breast.2026.104693_bib16","unstructured":"IBM Micromedex Red Book. Micromedex Solutions. Accessed August 23, 2025. http:\/\/www.micromedexsolutions.com."},{"key":"10.1016\/j.breast.2026.104693_bib17","article-title":"Adding enzalutamide to first-line treatment for metastatic hormone-sensitive prostate cancer: a cost-effectiveness analysis","volume":"9","author":"Zhang","year":"2021","journal-title":"Front Public Health"},{"key":"10.1016\/j.breast.2026.104693_bib18","doi-asserted-by":"crossref","first-page":"514","DOI":"10.18553\/jmcp.2018.24.6.514","article-title":"Cost-effectiveness of ribociclib plus Letrozole versus palbociclib plus Letrozole and Letrozole monotherapy in the first-line treatment of postmenopausal women with HR+\/HER2- advanced or metastatic breast cancer: a U.S. payer perspective","volume":"24","author":"Mistry","year":"2018","journal-title":"Journal of managed care & specialty pharmacy"},{"key":"10.1016\/j.breast.2026.104693_bib19","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920916000","article-title":"Cost-effectiveness of adding atezolizumab to first-line chemotherapy in patients with advanced triple-negative breast cancer","volume":"12","author":"Wu","year":"2020","journal-title":"Therapeutic advances in medical oncology"},{"key":"10.1016\/j.breast.2026.104693_bib20","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s40261-023-01325-z","article-title":"Is alpelisib plus fulvestrant cost-effective for treating PIK3CA-Mutation, HR+\/HER2- advanced breast cancer in the USA?","volume":"43","author":"Wu","year":"2023","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.breast.2026.104693_bib21","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/sj.bjc.6603326","article-title":"Health state utilities for metastatic breast cancer","volume":"95","author":"Lloyd","year":"2006","journal-title":"British journal of cancer"},{"key":"10.1016\/j.breast.2026.104693_bib22","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1159\/000357316","article-title":"Cost-Effectiveness of lapatinib plus letrozole in post-menopausal women with hormone receptor-and HER2-Positive metastatic breast cancer","volume":"8","author":"Delea","year":"2013","journal-title":"Breast Care"},{"key":"10.1016\/j.breast.2026.104693_bib23","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1016\/S1470-2045(13)70567-9","article-title":"Breast cancer in China","volume":"15","author":"Fan","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2026.104693_bib24","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.jval.2024.06.003","article-title":"Market entry agreements for innovative pharmaceuticals subject to indication broadening: a case study for pembrolizumab in the Netherlands","volume":"27","author":"Heine","year":"2024","journal-title":"Value Health : the journal of the International Society for Pharmacoeconomics and Outcomes Research"},{"key":"10.1016\/j.breast.2026.104693_bib25","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/S0140-6736(25)01011-6","article-title":"Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial","volume":"405","author":"Paz-Ares","year":"2025","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.breast.2026.104693_bib26","series-title":"The use of managed entry agreement in national reimbursement decisions of new drugs. ISPOR Europe 2020","year":"2020"},{"key":"10.1016\/j.breast.2026.104693_bib27","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.breast.2023.02.003","article-title":"Cost-effectiveness of sacituzumab govitecan versus chemotherapy in advanced or metastatic triple-negative breast cancer","volume":"68","author":"Lang","year":"2023","journal-title":"Breast"},{"key":"10.1016\/j.breast.2026.104693_bib28","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s40273-024-01456-x","article-title":"Cost-effectiveness of capivasertib as a second-line therapy for advanced breast cancer","volume":"43","author":"Nguyen","year":"2025","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.breast.2026.104693_bib29","article-title":"Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer","volume":"13","author":"Yang","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.breast.2026.104693_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.942767","article-title":"Economic evaluation of margetuximab vs. trastuzumab for pretreated ERBB2-positive advanced breast cancer in the US and China","volume":"10","author":"Tang","year":"2022","journal-title":"Front Public Health"},{"key":"10.1016\/j.breast.2026.104693_bib31","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jval.2023.11.004","article-title":"Cost-Effectiveness analysis of Trastuzumab Deruxtecan versus Trastuzumab emtansine for patients with human epidermal growth factor receptor 2 positive metastatic breast cancer in the United States","volume":"27","author":"Mudumba","year":"2024","journal-title":"Value Health : the journal of the International Society for Pharmacoeconomics and Outcomes Research"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626000032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626000032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T16:08:20Z","timestamp":1770998900000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977626000032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":31,"alternative-id":["S0960977626000032"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104693","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of inavolisib plus palbociclib-fulvestrant versus palbociclib plus fulvestrant as first-line treatment in HR+\/HER2-advanced breast cancer","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104693","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104693"}}